METHOD FOR TREATMENT OF SEVERE FORMS OF ATOPIC BRONCHIAL ASTHMA

摘要

the invention u043eu0442u043du043eu0441u0438u0442u0441u00a0 to medicine and can be used in the treatment of u0442u00a0u0436u0435u043bu044bu0445 forms of bronchial asthma.method u0437u0430u043au043bu044eu0447u0430u0435u0442u0441u00a0 in multiple u0442u0440u0430u043du0441u0444u0443u0437u0438u00a0u0445 u0440u0435u043du0442u0433u0435u043du043eu043eu0431u043bu0443u0447u0435u043du043du043eu0439 outside of the u0430u0443u0442u043eu043au0440u043eu0432u0438 (u0438u043du0442u0435u0433u0440u0430u043bu044cu043du0430u00a0 dose u043eu0431u043bu0443u0447u0435u043du0438u00a0 350 - 400 gr) under the control of t - lim u0444u043eu0446u0438 tov, their functional activity and t - soup - u0440u0435u0441u0441u043eu0440u043eu0432, u043fu0435u0440u0432u0430u00a0 u0442u0440u0430u043du0441u0444u0443u0437u0438u00a0 u043fu0440u043eu0432u043eu0434u0438u0442u0441u00a0 patients with u0442u00a0u0436u0435u043bu044bu043c in bronchial asthma in u043fu0440u0438u0441u0442u0443u043fu043du043eu043c period in with the characteristics of u043du0438u0436u0435u043du0438u0438 at 30% - 40% of normal.evidence of subsequent transfusions (3 to 6) u00a0u0432u043bu00a0u0435u0442u0441u00a0 data immunity decline, u043eu043fu0440u0435u0434u0435u043bu00a0u0435u043cu044bu0445 u0435u0436u0435u043cu0435u0441u00a0u0447u043du043e, 15% to 25% of normal u043du0435u0441u043cu043eu0442u0440u00a0 on clinical improvement with u0441u0442u043eu00a0u043du0438u00a0. the use of multiple u0442u0440u0430u043du0441u0444u0443u0437u0438u0439 u0440u0435u043du0442u0433u0435u043du043eu043eu0431u043bu0443u0447u0435u043du043du043eu0439 outside of the u0430u0443u0442u043eu043au0440u043eu0432u0438 under the control of the immune system u0441u043eu0441u0442u043eu00a0u043du0438u00a0 u043fu043eu0437u0432u043eu043bu00a0u0435u0442 u0434u043eu0431u0438u0442u044cu0441u00a0 counter (before nesque u043eu043bu044cu043au0438u0445 years) remission. 1, table 2).